Profile data is unavailable for this security.
About the company
Virpax Pharmaceuticals, Inc. is a preclinical-stage pharmaceutical company. The Company is focused on developing novel and proprietary drug delivery systems across various pain indication. Its drug-delivery systems and drug-releasing technologies being developed are focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system (CNS) disorders to enhance patients’ quality of life. Its portfolio consists of multiple preclinical stage product candidates: Epoladerm, Probudur, Envelta, AnQlar and NobrXiol. Probudur is a single injection liposomal bupivacaine formulation being developed to manage post-operative pain. Envelta is an intranasal molecular envelope enkephalin formulation being developed to manage acute and chronic pain, including pain associated with cancer. The NobrXiol is being developed for the nasal delivery of a pharmaceutical-grade cannabidiol (CBD) for the management of rare pediatric epilepsy.
- Revenue in USD (TTM)0.00
- Net income in USD-16.89m
- Incorporated2018
- Employees7.00
- LocationVirpax Pharmaceuticals Inc1055 Westlakes Drive, Suite 300BERWYN 19312United StatesUSA
- Phone+1 (610) 727-4597
- Fax+1 (302) 636-5454
- Websitehttps://virpaxpharma.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Health Advance Inc | -100.00bn | -100.00bn | 1.36m | 3.00 | -- | 0.3451 | -- | -- | -- | -- | -- | 0.0212 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.0356 | -- | 100.00 | -- | -21.75 | -- | -- | -- |
Aoxing Pharmaceutical Company Inc | 30.11m | -1.46m | 1.36m | 339.00 | -- | 0.016 | -- | 0.0453 | -0.0192 | -0.0192 | 0.3951 | 0.2507 | 0.496 | 2.32 | 2.56 | -- | -2.41 | -14.54 | -7.06 | -35.45 | 76.19 | 68.51 | -4.85 | -37.69 | 0.7368 | 0.3387 | 0.6052 | -- | 26.88 | 37.20 | -62.49 | -- | -38.80 | -- |
Sativus Tech Corp | 0.00 | -68.00k | 1.39m | -- | -- | -- | -- | -- | -0.0483 | -0.0483 | 0.00 | -0.5238 | 0.00 | -- | -- | -- | -18.83 | 25.48 | -- | -- | -- | -- | -- | -- | -- | -- | 5.41 | -- | -- | -- | 78.78 | -- | -- | -- |
Agentix Corp | 0.00 | -1.01m | 1.42m | -- | -- | -- | -- | -- | -0.0253 | -0.0253 | 0.00 | -0.071 | 0.00 | -- | -- | -- | -907.08 | -- | -- | -- | -- | -- | -- | -- | -- | -96.41 | -- | -- | -- | -- | -- | -- | -- | -- |
LadRx Corp | 0.00 | 1.66m | 1.44m | 2.00 | 0.842 | 4.16 | 0.8584 | -- | 3.44 | 3.44 | 0.00 | 0.6973 | 0.00 | -- | -- | 0.00 | 96.28 | -58.97 | -- | -78.44 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 106.96 | -- | -- | -- |
InVitro International | 716.89k | 6.22k | 1.44m | 16.00 | 180.29 | 1.96 | -- | 2.00 | 0.0004 | 0.0004 | 0.0402 | 0.0321 | 1.15 | -- | -- | -- | 0.995 | 7.89 | 1.09 | 8.83 | -- | -- | 0.8676 | 5.90 | -- | -- | -- | -- | -5.11 | 1.33 | -87.77 | -16.14 | -- | -- |
Dermata Therapeutics Inc | 0.00 | -8.69m | 1.45m | 8.00 | -- | 5.72 | -- | -- | -24.67 | -24.67 | 0.00 | 0.5717 | 0.00 | -- | -- | 0.00 | -120.05 | -- | -146.08 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 18.90 | -- | -- | -- |
Drazcanna Inc | 2.05m | -5.71m | 1.47m | -- | -- | -- | -- | 0.7192 | -0.7024 | -0.7024 | 0.2492 | 0.1004 | 0.685 | -- | 23.88 | -- | -191.19 | -- | -643.20 | -- | -11.20 | -- | -279.10 | -- | -- | -33.04 | 0.2445 | -- | -- | -- | -- | -- | -- | -- |
CTT Pharmaceutical Holdings Inc | 0.00 | -1.67m | 1.50m | 0.00 | -- | 0.8406 | -- | -- | -0.0822 | -0.0822 | 0.00 | 0.0346 | 0.00 | -- | -- | -- | -317.28 | 13.49 | -448.83 | 304.48 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -3,454.52 | -- | -- | -- |
Virpax Pharmaceuticals Inc | 0.00 | -16.89m | 1.50m | 7.00 | -- | -- | -- | -- | -14.42 | -14.42 | 0.00 | -1.04 | 0.00 | -- | -- | 0.00 | -156.21 | -87.52 | -241.52 | -116.56 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 29.84 | -- | -- | -- |
Bespoke Extracts Inc | 785.45k | -1.48m | 1.53m | 10.00 | -- | -- | -- | 1.94 | -0.1458 | -0.1458 | 0.0774 | -0.1696 | 2.06 | 55.99 | 34.73 | 78,545.00 | -388.21 | -- | -- | -- | 43.69 | -- | -188.79 | -- | 0.0612 | -135.42 | -- | -- | 22,933.72 | -- | 63.98 | -- | -- | -- |
180 Life Sciences Corp | 0.00 | -16.24m | 1.53m | 4.00 | -- | -- | -- | -- | -41.54 | -41.54 | 0.00 | -1.12 | 0.00 | -- | -- | 0.00 | -176.90 | -42.39 | -354.57 | -56.41 | -- | -- | -- | -- | -- | -385.88 | -- | -- | -- | -- | 48.52 | -- | -- | -- |
Bluejay Diagnostics Inc | 0.00 | -9.74m | 1.54m | 10.00 | -- | 0.4231 | -- | -- | -7.68 | -7.68 | 0.00 | 1.25 | 0.00 | -- | -- | 0.00 | -122.06 | -- | -149.68 | -- | -- | -- | -- | -- | -- | -- | 0.0048 | -- | -100.00 | -- | -7.07 | -- | -- | -- |
Cannabis Suisse Corp | 30.00k | -254.75k | 1.58m | -- | -- | -- | -- | 52.66 | -0.0057 | -0.0057 | 0.0007 | -0.0103 | 0.0675 | -- | -- | -- | -57.35 | -149.71 | -238.71 | -- | 8.37 | -39.11 | -849.17 | -427.20 | -- | -13.57 | 3.38 | -- | 28.70 | 9.00 | -87.10 | -- | -- | -- |
Mallinckrodt PLC | 1.91bn | -1.49bn | 1.60m | 2.80k | -- | -- | -- | 0.0008 | -161.65 | -161.63 | 89.63 | 55.44 | 0.4062 | 1.57 | 4.94 | 681,821.40 | -31.61 | -12.49 | -36.10 | -15.85 | 26.22 | 35.68 | -77.83 | -44.38 | 1.63 | -0.3456 | 0.6164 | -- | -2.53 | -10.31 | -83.00 | -- | -- | -- |
Procyon Corp | 4.70m | -314.48k | 1.62m | 17.00 | -- | 0.7287 | -- | 0.345 | -0.0388 | -0.0388 | 0.5804 | 0.2901 | 1.40 | 1.95 | 8.58 | 276,481.20 | -8.90 | 3.52 | -10.60 | 4.23 | 77.60 | 73.30 | -6.35 | 2.52 | 2.70 | -- | 0.00 | -- | -3.22 | 3.11 | 70.44 | -- | 30.98 | -- |
Holder | Shares | % Held |
---|---|---|
Tower Research Capital LLCas of 31 Mar 2024 | 1.45k | 0.12% |
Signature Resources Capital Management LLCas of 31 Mar 2024 | 500.00 | 0.04% |
FSC Securities Corp.as of 30 Sep 2023 | 60.00 | 0.01% |
Morgan Stanley Smith Barney LLC (Investment Management)as of 31 Mar 2024 | 15.00 | 0.00% |
Wells Fargo Bank, NA (Private Banking)as of 31 Mar 2024 | 8.00 | 0.00% |
Parallel Advisors LLCas of 31 Mar 2024 | 1.00 | 0.00% |
Sheets Smith Wealth Managementas of 31 Mar 2024 | 0.00 | 0.00% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 0.00 | 0.00% |
Renaissance Technologies LLCas of 31 Mar 2024 | 0.00 | 0.00% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 0.00 | 0.00% |